急性胰腺炎患者报告结局量表的设计与验证:PAN-PROMISE研究
本研究基于患者、专业人员和专家组的意见设计了急性胰腺炎患者报告结局量表(PAN-PROMISE),并在国际多中心前瞻性队列中验证。验证队列涵盖15个国家524例患者,量表包含7个条目,具有良好的内部一致性、重测信度、结构效度和效标效度。PAN-PROMISE可作为临床试验终点和随访中量化患者健康状况的工具。
要点
- PAN-PROMISE为7条目量表,聚焦急性胰腺炎患者最不适和最担忧的症状。
- 验证队列涉及15国524例患者,量表呈单维有序结构且拟合指标良好。
- 出院时内部一致性和分半信度 adequate,重测信度支持可重复性。
核心结论
- PAN-PROMISE量表可作为急性胰腺炎临床试验的终点工具,并用于量化患者住院期间和随访中的健康状况。
研究设计与样本
- 基于患者、专业人员和专家组的意见设计PROM工具,并在国际多中心前瞻性队列研究中验证。
- 验证队列涉及15个国家524例患者,以出院后15天急性胰腺炎严重程度和生活质量为主要验证变量。
- 应用COSMIN方法学,评估内容效度、面效度、计量属性、信度、结构效度、效标效度、反应度和可解释性。
主要发现
- PAN-PROMISE由7个条目组成,基于对急性胰腺炎患者造成最大不适和担忧的症状。
- 症状强度从最初24小时较高值降至出院时和出院后15天的较低值。
- 条目汇聚为单维有序量表,拟合指标良好。
- 出院时内部一致性和分半信度 adequate,通过重测信度及比较出院时和出院后15天评分确认可重复性。
- 提供了聚合-区分效度和实证效度的证据。
临床怎么用
- 可将PAN-PROMISE作为急性胰腺炎临床试验中以患者为中心的终点指标。
- 可用于住院期间和随访中量化急性胰腺炎患者的健康状况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. DESIGN: A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. RESULTS: PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test-retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. CONCLUSION: The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up. TRIAL REGISTRATION NUMBER: NCT03650062.
引用
- de-Madaria E, Sánchez-Marin C, Carrillo I, et al. Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut. 2020. PMID: 32245906. doi:10.1136/gutjnl-2020-320729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。